Search clinical trials for: PF-06651600 20 mg

Total 974 results

Pfizer

Completed

PF-06651600 Taste Study.

Healthy Participants

Belgium
Pfizer

Completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of PF-06651600 in Subjects With Hepatic Impairment and Healthy Volunteers

Hepatic Impairment | Healthy Participants

United States
Pfizer

Completed

A Target Occupancy Study With Ritlecitinib.

Healthy

United States
Pfizer

Completed

PF-06651600 for the Treatment of Alopecia Areata (ALLEGRO-2b/3)

Alopecia Areata

China, United States, Spain, Korea, Republic of, Taiwan, Canada, Australia, Germany, Czechia, Poland, Hungary, Japan, United Kingdom, Argentina, Chile, Colombia, Mexico, Russian Federation
Pfizer

Completed

Study to Characterize Absorption, Distribution, Metabolism and Excretion of 14C PF-06651600 and to Evaluate the Absolute Oral Bioavailability and Fraction Absorbed of PF-06651600. (B7981011)

Healthy Volunteers

Netherlands
Pfizer

Completed

A DRUG-DRUG INTERACTION STUDY BETWEEN PF-06650833 AND PF-06651600 FOLLOWING MULTIPLE DOSES IN HEALTHY PARTICIPANTS

Healthy

United States
Pfizer

Completed

Bioequivalence Study of PF-06651600 Capsules Relative to Tablets and Estimation of Food Effect on Capsules.

Healthy Participants

United States
Pfizer

Terminated

A Renal Impairment Study for PF-06651600

Renal Impairment

United States
Pfizer

Completed

PHARMACOKINETIC CHARACTERIZATION OF PF-06651600 IN CHINESE ADULT PARTICIPANTS

Healthy Participants

China
Emma Guttman
Pfizer

Recruiting

Ritlecitinib for Cicatricial Alopecia

Cicatricial Alopecia

United States
Pfizer

Completed

Safety and Pharmacokinetic Study of PF-06651600 in Japanese Healthy Volunteers

Healthy

Belgium
Pfizer

Completed

A Study To Evaluate The PDE10 Enzyme Occupancy Following A Single Dose Of PF-02545920 In Healthy Male Volunteers (PET)

Healthy

Sweden
Pfizer

Completed

STUDY OF PF-06882961 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WITH VARYING DEGREES OF RENAL IMPAIRMENT AND PARTICIPANTS WITHOUT RENAL IMPAIRMENT

Healthy | Diabetes Mellitus, Type 2 | Renal Impairment

United States
Pfizer

Completed

Bioavailability Study of PF-06651600 Formulations in Healthy Participants

Healthy Volunteers

Belgium
Pfizer

Completed

A Study to Compare Two Different Forms of PF-07081532 in Adults Who Are Overweight or Obese

Obesity | Overweight

United States
Pfizer

Completed

Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease

Crohn's Disease

United States, Spain, Lebanon, Australia, Russian Federation, Korea, Republic of, Tunisia, Italy, Poland, Belgium, Austria, Germany, Saudi Arabia, Czechia, Hungary, Switzerland, Turkey, Slovakia, Ukraine, Georgia, Bosnia and Herzegovina and more
Pfizer

Completed

A Study To Investigate How The Body Handles Multiple Doses Of PF-0243873 And To Investigate The Effect Of PF-02413873 On Sex Hormone Levels In Healthy Young Women

Endometriosis

United States, Belgium
Pfizer

Terminated

Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021

Huntington's Disease

United States, Germany, Poland, United Kingdom, Canada
Pfizer

Completed

Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

United States, Spain, Israel, Korea, Republic of, Russian Federation, Turkey, Czechia, Hungary, Italy, Poland, Bulgaria, Denmark, Germany, Serbia, Austria, Slovakia, Ukraine, Georgia, Romania
Pfizer

Completed

12 Week Study Of PF-00734200 For The Treatment Of Type 2 Diabetes Mellitus In Subjects Treated With Metformin

Diabetes Mellitus, Type 2

United States, Colombia, Spain, Germany, Sweden, Italy
Pfizer

Completed

Bioavailability Study Of PF-06651600 In Healthy Subjects

Healthy

Belgium
Pfizer

Completed

Safety and Pharmacokinetic Study of PF-06651600 in Healthy Volunteers

Healthy

Belgium
Pfizer

Recruiting

A Study to Learn About How Different Forms of the Study Medicine Called Ritlecitinib Pass the Intestines of Healthy Male Adults When Taken With or Without Food

Healthy Volunteers

United States
Pfizer

Completed

A Study to Learn About Three Forms of The Study Medicine (Ritlecitinib) in Healthy Adults

Healthy Volunteers

Belgium
Pfizer

Completed

Effect of PF-00734200 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2

Canada, United States, Korea, Republic of, Puerto Rico
Pfizer

Completed

A Study to Assess Two Forms of The Study Medicine (Ritlecitinib) in Healthy Adult Participants

Healthy Volunteers | Pharmacokinetics | Adult

Belgium
Pfizer

Completed

Study to Evaluate the Effect of Multiple-Dose Ritlecitinib on the Pharmacokinetics (PK) of Tolbutamide

Healthy Volunteers

United States
Pfizer

Completed

Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata

Alopecia Areata

United States, Canada, Australia
Pfizer

Completed

Study To Evaluate Safety, Tolerability, And Pharmacokinetics Of PF-06473871 In Normal Healthy Adults

Healthy

Belgium
Pfizer

Completed

A Study To Observe Safety And Blood Concentrations Of PF-06412562 During And Following The Oral Administration Of Multiple Doses Of PF-06412562 In Healthy Adult Volunteers

Healthy

United States
Pfizer

Completed

A Study To Observe Safety And Concentrations Of PF-05297909 And Proteins In Both Blood And Cerebrospinal Fluid After A Single Dose Of PF-05297909 In Healthy Adults

Healthy

United States
Pfizer

Terminated

PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA (Allegro2a)

Alopecia Areata

United States, Australia, Canada, Poland
Pfizer

Completed

A Study To Observe Safety And Blood Concentrations Of PF-04995274 During And Following the Administration of Multiple Doses Of PF-04995274 In Healthy Adult And Healthy Elderly Volunteers.

Healthy

United States
Pfizer

Completed

A Study To Observe Safety And Blood Concentrations Of PF-06649751 During And Following The Oral Administration Of Multiple Doses Of PF-06649751 In Healthy Adult Western and Japanese Volunteers

Healthy

United States
Pfizer

Completed

Study To Assess The Efficacy And Safety Of Pf-06651600 In Subjects With Rheumatoid Arthritis With An Inadequate Response To Methotrexate

Rheumatoid Arthritis

United States, Poland, Serbia, Slovakia, Czechia, Georgia, Germany, Bulgaria, Hungary
Pfizer

Completed

A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects

Active Non-segmental Vitiligo

Spain, United States, Korea, Republic of, Taiwan, Canada, Australia, Germany, Japan, Belgium, Italy
Pfizer

Withdrawn

A Study To Look At Safety And Blood Concentrations After Multiple Doses Of PF-03382792 In Healthy Elderly Individuals

Healthy
Pfizer

Completed

Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

Korea, Republic of, Canada, United States, Australia, United Kingdom, Belgium
Pfizer

Terminated

A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)

Multiple Sclerosis

United States
Pfizer

Withdrawn

A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis

Ulcerative Colitis

United States
Pfizer

Completed

Single Dose Escalation Study of PF-04360365 In Subjects With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

United States
Pfizer

Completed

Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus

Diabetes Melliuts, Type 2

United States
Hoffmann-La Roche
Pfizer

Completed

A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis

Moderate to Severe Ulcerative Colitis

United States, Australia, Thailand, Poland, Russian Federation, Japan, Colombia, Spain, Turkey, Romania, India, Slovakia, France, Hungary, South Africa, Belgium, Bulgaria, Germany, Italy, Mexico, Serbia, Ukraine, United Kingdom
Pfizer

Completed

TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE

Rheumatoid Arthritis

Czechia, Hungary, Spain, Poland, Canada, Bulgaria, Chile, Georgia, Slovakia, Ukraine
Pfizer
Medivation, Inc.

Terminated

A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease

Alzheimer Disease

United States, Hungary, Germany, Spain, Turkey, Slovakia, Canada, Portugal
Pfizer

Completed

Study To Characterize Mass Balance, Absolute Bioavailability, Fraction Absorbed And Pharmacokinetics Of 14C PF-06882961

Healthy Volunteer

Netherlands
Pfizer

Completed

A Study To Evaluate D1 Receptor Occupancy (RO) Following Single Dose of PF-06412562 In Healthy Male Volunteers (PET)

Healthy

Sweden
Pfizer

Completed

A Healthy Volunteer Trial to Gain Information About the Blood Concentrations of PF-06412562 After Oral Administration of a Modified Release Formulation in Fasted and Fed Conditions

Healthy

Belgium
Pfizer

Terminated

Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations

Parkinson's Disease With Motor Fluctuations

United States
Vanda Pharmaceuticals

Completed

Open Label Study to Assess the Absolute Bioavailability of Tasimelteon (HETLIOZ™)

Non-24-Hour-Sleep-Wake Disorder

3

Subscribe